AR and prostate carcinoma: This systematic review and meta-analysis examines 11 randomized clinical trials to see whether therapy with androgen receptor inhibitors (ARIs), such as enzalutamide, apalutamide, or darolutamide, is associated with an increased risk of falls and fractures in men with prostate cancer.